Regeneron Pharmaceuticals, Inc.

Symbol: REGN

NASDAQ

946.87

USD

Market price today

  • 25.5302

    P/E Ratio

  • -1.9206

    PEG Ratio

  • 102.21B

    MRK Cap

  • 0.00%

    DIV Yield

Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & Analysis

Shares Outstanding

107.94M

Gross Profit Margin

0.90%

Operating Profit Margin

0.31%

Net Profit Margin

0.30%

Return on Assets

0.12%

Return on Equity

0.15%

Return on Capital Employed

0.12%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Leonard S. Schleifer M.D., Ph.D.
Full-time employees:13450
City:Tarrytown
Address:777 Old Saw Mill River Road
IPO:1991-04-02
CIK:0000872589

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

General Outlook

In simple terms, Regeneron Pharmaceuticals, Inc. has 107.944 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.902% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.309%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.301%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.120% return, is a testament to Regeneron Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Regeneron Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.154%. Furthermore, the proficiency of Regeneron Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable 0.125% return on capital employed.

Stock Prices

Regeneron Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $964.93, while its low point bottomed out at $937.47. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Regeneron Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing REGN liquidity ratios reveals its financial health of the firm. The current ratio of 4181.88% gauges short-term asset coverage for liabilities.

cards.indicatorcards.value
Current Ratio4181.88%
Quick Ratio3741.22%

Profitability Ratios

REGN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 32.01% underscores its earnings before tax deductions. The effective tax rate stands at 5.85%, revealing its tax efficiency. The net income per EBT, 94.15%, and the EBT per EBIT, 103.76%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 30.85%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin32.01%
Effective Tax Rate5.85%
Net Income per EBT94.15%
EBT per EBIT103.76%
EBIT per Revenue30.85%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 41.82, it details the span from stock purchase to revenue. The 37 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding3741
Days of Inventory Outstanding733
Operating Cycle890.97
Cash Conversion Cycle891
Receivables Turnover2.31
Inventory Turnover0.50
Fixed Asset Turnover3.16
Asset Turnover0.40

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 32.87, and free cash flow per share, 28.49, depict cash generation on a per-share basis. The cash per share value, 152.36, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.27, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share32.87
Free Cash Flow per Share28.49
Cash per Share152.36
Operating Cash Flow Sales Ratio0.27
Free Cash Flow to Operating Cash Flow Ratio0.87
Cash Flow Coverage Ratio1.77
Capital Expenditure Coverage Ratio7.50
Dividend Paid and Capex Coverage Ratio7.50

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 5.99%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 6.10%, and total debt to capitalization, 6.10%, ratios shed light on its capital structure. An interest coverage of 5058.88 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio5.99%
Debt Equity Ratio0.06
Long Term Debt to Capitalization6.10%
Total Debt to Capitalization6.10%
Interest Coverage5058.88
Cash Flow to Debt Ratio1.77
Company Equity Multiplier1.08

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 122.94, provides a glimpse into top-line earnings distributed across each share. Net income per share, 37.05, reflects the portion of profit attributed to each share. The book value per share, 243.42, represents the net asset value distributed per share, while the tangible book value per share, 233.69, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share122.94
Net Income Per Share37.05
Book Value Per Share243.42
Tangible Book Value Per Share233.69
Shareholders Equity Per Share243.42
Interest Debt Per Share24.65
Capex Per Share-5.53

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 7.76%, indicates top-line expansion, while the gross profit growth, 15.27%, reveals profitability trends. EBIT growth, -14.60%, and operating income growth, -14.60%, offer insights into operational profitability progression. The net income growth, -8.87%, showcases bottom-line expansion, and the EPS growth, -8.54%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth7.76%
Gross Profit Growth15.27%
EBIT Growth-14.60%
Operating Income Growth-14.60%
Net Income Growth-8.87%
EPS Growth-8.54%
EPS Diluted Growth-9.03%
Weighted Average Shares Growth-6.00%
Weighted Average Shares Diluted Growth0.18%
10-Year Revenue Growth per Share549.62%
5-Year Revenue Growth per Share110.33%
3-Year Revenue Growth per Share66.54%
10-Year Operating CF Growth per Share788.10%
5-Year Operating CF Growth per Share145.83%
3-Year Operating CF Growth per Share106.65%
10-Year Net Income Growth per Share871.12%
5-Year Net Income Growth per Share74.04%
3-Year Net Income Growth per Share21.41%
10-Year Shareholders Equity Growth per Share1286.90%
5-Year Shareholders Equity Growth per Share219.14%
3-Year Shareholders Equity Growth per Share154.15%
Receivables Growth6.35%
Inventory Growth7.44%
Asset Growth13.23%
Book Value per Share Growth21.92%
Debt Growth0.06%
R&D Expense Growth23.56%
SGA Expenses Growth24.36%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 93,686,443,000, captures the company's total value, considering both debt and equity. The ratio of intangibles to total assets, 3.14%, indicates the value of non-physical assets, and capex to operating cash flow, -11.77%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value93,686,443,000
Research and Development to Revenue33.84%
Intangibles to Total Assets3.14%
Capex to Operating Cash Flow-11.77%
Capex to Revenue-4.50%
Graham Number450.49
Return on Tangible Assets12.34%
Graham Net Net86.96
Working Capital16,055,800,000
Tangible Asset Value24,934,500,000
Net Current Asset Value12,372,100,000
Average Receivables5,498,000,000
Average Payables597,900,000
Average Inventory2,491,200,000
Days Sales Outstanding158
Days Payables Outstanding251
Days of Inventory On Hand1066
ROIC12.96%
ROE0.15%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.31, and the price to book ratio, 3.31, reflect the market's valuation relative to the company's book value. The price to sales ratio, 7.79, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 33.65, and price to operating cash flows, 28.80, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.31
Price to Book Ratio3.31
Price to Sales Ratio7.79
Price Cash Flow Ratio28.80
Price Earnings to Growth Ratio-1.92
Enterprise Value Multiple23.20
Price Fair Value3.31
Price to Operating Cash Flow Ratio28.80
Price to Free Cash Flows Ratio33.65
Price to Tangible Book Ratio3.61
Enterprise Value to Sales7.14
Enterprise Value Over EBITDA23.15
EV to Operating Cash Flow18.68
Earnings Yield4.22%
Free Cash Flow Yield4.72%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Regeneron Pharmaceuticals, Inc. (REGN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 25.530 in 2024.

What is the ticker symbol of Regeneron Pharmaceuticals, Inc. stock?

The ticker symbol of Regeneron Pharmaceuticals, Inc. stock is REGN.

What is company IPO date?

IPO date of Regeneron Pharmaceuticals, Inc. is 1991-04-02.

What is company current share price?

Current share price is 946.870 USD.

What is stock market cap today?

The market cap of stock today is 102208935280.000.

What is PEG ratio in 2024?

The current -1.921 is -1.921 in 2024.

What is the number of employees in 2024?

In 2024 the company has 13450.